Nyrada (ASX:NYR) Dividend Yield % : 0.00% (As of May. 19, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Nyrada Dividend Yield %?

As of today (2024-05-19), the Trailing Annual Dividend Yield of Nyrada is 0.00%.

The historical rank and industry rank for Nyrada's Dividend Yield % or its related term are showing as below:

ASX:NYR's Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.36
* Ranked among companies with meaningful Dividend Yield % only.

Nyrada's Dividend Payout Ratio for the six months ended in Dec. 2023 was 0.00.

As of today (2024-05-19), the Forward Dividend Yield % of Nyrada is 0.00%.

Nyrada's Dividends per Share for the six months ended in Dec. 2023 was A$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Nyrada Dividend Yield % Historical Data

The historical data trend for Nyrada's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada Dividend Yield % Chart

Nyrada Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Dividend Yield %

Nyrada Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Dividend Yield %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Nyrada's Dividend Yield %

For the Biotechnology subindustry, Nyrada's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nyrada's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nyrada's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Nyrada's Dividend Yield % falls into.

Nyrada Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Nyrada (ASX:NYR) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Nyrada Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Nyrada's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nyrada (ASX:NYR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072

Website

https://www.nyrada.com

Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines